Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 439 of 5804
-
Can triple therapy kickstart diabetes remission? new study aims to find out
Disease control Recruiting nowThis study is a multicenter, randomized, controlled study. A sample size of 240 cases is proposed to be included. The inclusion criteria are: (1) patients with newly diagnosed type 2 diabetes; (2) age between 18 and 65 years old; (3) HbA1c ≥ 9.0%. The exclusion criteria include: …
Phase: PHASE1, PHASE2 • Sponsor: Second Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
AI could predict which prostate cancers turn aggressive
Knowledge-focused OngoingThis study aims to develop an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing castration-resistant prostate cancer (CRPC), a more severe form of the disease. The study will use pre-treatment MRI images, biopsy…
Sponsor: Guangxi Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New drug cocktail aims to tackle tough breast cancer
Disease control Recruiting nowThis study aims to evaluate the safety and effectiveness of JSKN016 in combination with different treatments for patients with HER2-negative breast cancer that cannot be removed by surgery or has spread to other parts of the body. The study includes four groups of patients based …
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 18:35 UTC
-
New heart valve replacement could offer hope for severe leakage
Disease control Recruiting nowProspective, multi-center study to assess safety and performance of the inQB8 MonarQ Tricuspid Valve Replacement System.
Phase: NA • Sponsor: inQB8 Medical Technologies, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for advanced breast cancer: combination therapy trial launches
Disease control Recruiting nowThis is a Study to Evaluate the Efficacy and Safety of Multiple Combination Therapies with FWD1802 in Subjects with ER-positive/HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
Phase: PHASE1, PHASE2 • Sponsor: Forward Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New immune cell therapy takes on virus after transplant
Disease control Recruiting nowEpstein-Barr virus (EBV) DNAemia is a common and potentially serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and may progress to EBV-associated lymphoproliferative disorders. Current treatment options are limited, and effective immune-bas…
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Immunotherapy plus chemo shows promise against rectal cancer
Disease control Recruiting nowTo evaluate the safety and preliminary efficacy of preoperative chemotherapy and PD-1 inhibitor Tislelizumab for Rectal Cancer patients.Go through laboratory and medical tests to verify eligibility to enter the study, receive the experimental combination of drugs CAPOX (Oxaliplat…
Phase: PHASE2 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New combo may let some colon cancer patients skip surgery
Disease control Recruiting nowThe PICC-3 study is a multicentre, single-arm, phase II trial evaluating toripalimab plus celecoxib in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer. The trial uses a response-adapted treatment strateg…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New Blood-Cleansing method boosts transplant success in High-Risk patients
Disease control CompletedThis study reviews patients who received haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Some patients develop donor-specific antibodies (DSA), which can block engraftment and cause transplant failure. Before transplant, a treatment called protein A immunoads…
Sponsor: Ting YANG • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New balloon treatment could change how heart attacks are treated
Disease control Recruiting nowAcute ST-segment elevation myocardial infarction (STEMI) is a life-threatening emergency requiring immediate intervention. The incidence of premature coronary artery disease (PCAD) is rising rapidly in China; its long-term prognosis remains poor and it frequently progresses to ac…
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could a bone marrow transplant free kidney patients from lifelong pills?
Disease control Recruiting nowThis is an open-label, single-institution study to assess the safety and the efficacy of the Sip-Tego regimen for the induction of donor-specific immunologic unresponsiveness to a renal allograft. The investigators propose to treat 6 adult subjects in end-stage renal disease (ESR…
Phase: EARLY_PHASE1 • Sponsor: Tatsuo Kawai, MD, PhD • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Massive study tests whether a stronger flu shot saves more seniors from hospitalization
Prevention CompletedThis prespecified analysis will pool the datasets from two pragmatic randomized trials evaluating the relative vaccine effectiveness of high-dose vs. standard-dose influenza vaccine against severe clinical outcomes: the DANFLU-2 (A Pragmatic Randomized Trial to Evaluate the Effec…
Phase: PHASE4 • Sponsor: Tor Biering-Sørensen • Aim: Prevention
Last updated Jun 26, 2026 16:37 UTC
-
New hope for hard-to-treat cancers: targeted combo trial opens
Disease control Recruiting nowTNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose e…
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Blood test could replace colonoscopy for cancer screening?
Diagnosis Recruiting nowThe FIND-CRC study is a prospective collection of samples and data from participants who are at average risk of developing colorectal cancer (CRC). Collected samples and data will be analyzed to evaluate the clinical performance of the Natera CRC Screening Test.
Sponsor: Natera, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
New hope for tough leukemia? early trial of debio 1562M begins
Disease control Recruiting nowThe primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization). The primary objective of Phase 2 is to evaluate the antileukemic activity of Debio 1562M.
Phase: PHASE1, PHASE2 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control OngoingThis study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
Phase: PHASE2 • Sponsor: Aclaris Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Gene therapy injection takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Lung cancer trial tests Two-Drug immune attack for Hard-to-Treat tumors
Disease control Recruiting nowThe purpose of this study, known as DISCERN, is to compare two different treatments for a type of lung cancer called non-small cell lung cancer (NSCLC) that does not show a marker known as PD-L1. This study will help us understand if using two types of immune therapy together wit…
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
MRI-Guided boost: could a higher radiation dose beat esophageal cancer?
Disease control Recruiting nowSUMMARY Rationale: Esophageal cancer (EC) is the seventh most frequently diagnosed cancer and the sixth leading cause of cancer-related death worldwide. As a result of the late onset of symptoms, most patients with EC present in an advanced stage with a corresponding poor prognos…
Phase: PHASE1 • Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
AI could spare thousands from unnecessary prostate biopsies
Diagnosis Recruiting nowThis is a multicenter observational study. A deep learning model integrated with multimodal imaging and digital pathology spatial registration is built based on preoperative multiparametric magnetic resonance imaging, transrectal ultrasound and postoperative digital pathological …
Sponsor: Guangxi Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC